Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration

Addressing coronavirus disease 2019 (COVID-19) vaccine hesitancy and minimizing potential vaccine contraindications are critical to combatting the pandemic. We describe a practical approach to immediate adverse events after the first dose of messenger RNA vaccines for severe acute respiratory syndro...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanijcharoenkarn, Kristine, Lee, Frances Eun-Hyung, Martin, Lindsay, Shih, Jennifer, Sexton, Mary Elizabeth, Kuruvilla, Merin Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194535/
https://www.ncbi.nlm.nih.gov/pubmed/33989390
http://dx.doi.org/10.1093/cid/ciab448
_version_ 1783706424142987264
author Vanijcharoenkarn, Kristine
Lee, Frances Eun-Hyung
Martin, Lindsay
Shih, Jennifer
Sexton, Mary Elizabeth
Kuruvilla, Merin Elizabeth
author_facet Vanijcharoenkarn, Kristine
Lee, Frances Eun-Hyung
Martin, Lindsay
Shih, Jennifer
Sexton, Mary Elizabeth
Kuruvilla, Merin Elizabeth
author_sort Vanijcharoenkarn, Kristine
collection PubMed
description Addressing coronavirus disease 2019 (COVID-19) vaccine hesitancy and minimizing potential vaccine contraindications are critical to combatting the pandemic. We describe a practical approach to immediate adverse events after the first dose of messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2, focusing on diagnosis and management of allergic reactions.
format Online
Article
Text
id pubmed-8194535
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-81945352021-06-15 Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration Vanijcharoenkarn, Kristine Lee, Frances Eun-Hyung Martin, Lindsay Shih, Jennifer Sexton, Mary Elizabeth Kuruvilla, Merin Elizabeth Clin Infect Dis Brief Reports Addressing coronavirus disease 2019 (COVID-19) vaccine hesitancy and minimizing potential vaccine contraindications are critical to combatting the pandemic. We describe a practical approach to immediate adverse events after the first dose of messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2, focusing on diagnosis and management of allergic reactions. Oxford University Press 2021-05-14 /pmc/articles/PMC8194535/ /pubmed/33989390 http://dx.doi.org/10.1093/cid/ciab448 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
spellingShingle Brief Reports
Vanijcharoenkarn, Kristine
Lee, Frances Eun-Hyung
Martin, Lindsay
Shih, Jennifer
Sexton, Mary Elizabeth
Kuruvilla, Merin Elizabeth
Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
title Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
title_full Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
title_fullStr Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
title_full_unstemmed Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
title_short Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
title_sort immediate reactions after the first dose of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) messenger rna vaccines do not preclude second-dose administration
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194535/
https://www.ncbi.nlm.nih.gov/pubmed/33989390
http://dx.doi.org/10.1093/cid/ciab448
work_keys_str_mv AT vanijcharoenkarnkristine immediatereactionsafterthefirstdoseofsevereacuterespiratorysyndromecoronavirus2sarscov2messengerrnavaccinesdonotprecludeseconddoseadministration
AT leefranceseunhyung immediatereactionsafterthefirstdoseofsevereacuterespiratorysyndromecoronavirus2sarscov2messengerrnavaccinesdonotprecludeseconddoseadministration
AT martinlindsay immediatereactionsafterthefirstdoseofsevereacuterespiratorysyndromecoronavirus2sarscov2messengerrnavaccinesdonotprecludeseconddoseadministration
AT shihjennifer immediatereactionsafterthefirstdoseofsevereacuterespiratorysyndromecoronavirus2sarscov2messengerrnavaccinesdonotprecludeseconddoseadministration
AT sextonmaryelizabeth immediatereactionsafterthefirstdoseofsevereacuterespiratorysyndromecoronavirus2sarscov2messengerrnavaccinesdonotprecludeseconddoseadministration
AT kuruvillamerinelizabeth immediatereactionsafterthefirstdoseofsevereacuterespiratorysyndromecoronavirus2sarscov2messengerrnavaccinesdonotprecludeseconddoseadministration

Ejemplares similares